16 completed, 3 terminated, 2 active not recruiting, 1 recruiting. 15 Phase 2, 8 Phase 1, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Active not recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 8 | Completed 5, Active not recruiting 1, Terminated 1, Unknown 1 |
| Early Phase 1 | 2 | Completed 1, Terminated 1 |
Follow this condition Literature Review of Therapy-Related Acute Myeloid Leukemia trials Research Report on Therapy-Related Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clonal Hematopoiesis Chemotherapy and Radiation Effects Study Samples - Lung Cancer (Diagnosis), Osteochondroma | Recruiting | Dana-Farber Cancer Institute | 5000 | 2025-04-04 | 2026-06-30 | |
| VYxeoS Liposomal Italian Observational Study iN the Real Practice Vyxeos liposomal - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Completed | Jazz Pharmaceuticals | 113 | 2023-12-07 | 2025-11-20 | |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Azacitidine, Dubermatinib - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Early Phase 1 | Completed | Uma Borate | 3 | 2020-11-05 | 2023-02-06 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2020-05-05 | 2026-10-05 |
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Azacitidine, Venetoclax - Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation | Phase 2 | Terminated | M.D. Anderson Cancer Center | 36 | 2019-09-13 | 2026-10-16 |
| A Post-Marketing Observational Study of VYXEOS™ CPX-351 - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia | Completed | Jazz Pharmaceuticals | 52 | 2018-10-23 | 2020-08-05 | |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Cytarabine, Idarubicin, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 53 | 2018-04-18 | 2026-06-01 |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia Decitabine, Laboratory Biomarker Analysis, Pevonedistat - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | City of Hope Medical Center | 12 | 2017-08-21 | 2026-04-22 |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Cytarabine, Decitabine, Idarubicin - Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | University of Nebraska | 75 | 2017-07-07 | 2026-03-10 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Cytarabine, Vosaroxin - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 42 | 2016-03-01 | 2025-04-15 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Pacritinib, Cytarabine, Daunorubicin Hydrochloride - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 13 | 2016-01-12 | 2019-01-25 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Ipilimumab, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 150 | 2015-04-07 | 2025-06-08 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2014-04-22 | 2024-01-24 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 63 | 2013-06-11 | 2023-11-07 |
| NK Cells in Cord Blood Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 1 | Unknown | M.D. Anderson Cancer Center | 13 | 2013-05-03 | 2020-02-11 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Fludarabine phosphate, Busulfan, Total-Body Irradiation - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 62 | 2012-12-24 | 2025-10-30 |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 47 | 2012-12-06 | 2022-07-14 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Myeloid, Acute (18) · Myelodysplastic Syndromes (7) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Accelerated Phase (3) · Blast Crisis (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Chronic-Phase (2) · Leukemia, Myelomonocytic, Acute (2) · Multiple Myeloma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Primary Myelofibrosis (2)
Neoplasms (21) · Neoplasms by Histologic Type (21) · Hemic and Lymphatic Diseases (20) · Leukemia (20) · Hematologic Diseases (19) · Leukemia, Myeloid (18) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Bone Marrow Diseases (7) · Chronic Disease (6) · Disease Attributes (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6)
Cytarabine (8) · Azacitidine (5) · Cyclophosphamide (5) · Decitabine (5) · Injections (5) · fludarabine phosphate (5) · CPX-351 (4) · Peripheral Blood Stem Cell Transplantation (4) · Tacrolimus (4) · Whole-Body Irradiation (4) · venetoclax (4) · Busulfan (3) · Daunorubicin (3) · Mycophenolic Acid (3) · Idarubicin (2)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (4) · Fred Hutchinson Cancer Center (2) · Jazz Pharmaceuticals (2) · Bhavana Bhatnagar (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Roswell Park Cancer Institute (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Uma Borate (1) · University of Nebraska (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
United States (23) · Italy (1)
Guido Marcucci (2) · Alice Mims (1) · Aude Chapuis (1) · Betul Oran (1) · Bhavana Bhatnagar, DO (1) · Chitra Hosing (1) · Dolores Grosso, RN, CRNP, DNP (1) · Eunice Wang, MD (1) · Gail J Roboz (1) · Geoffrey L Uy (1) · Kevin Kelly, MD (1) · Lachelle D Weeks, MD, PhD (1) · Masumi Ueda Oshima (1) · Michael Savona, MD (1) · Naval Daver (1)
PMID 31171508, PMID 36184192, PMID 29034366, PMID 29042364, PMID 29567781, PMID 30567725, PMID 31235963, PMID 31668825, PMID 32092139, PMID 34162404, PMID 34312462, PMID 34980577, PMID 35420672, PMID 35450817, PMID 38000343, PMID 38391202, PMID 38548404, PMID 40298352
U10CA031946 (3), U10CA180821 (3), P01CA018029 (1), P01CA049639 (1), P30CA014089 (1), P30CA016058 (1), P30CA016672 (1), P30CA033572 (1), P30CA036727 (1), P30CA068485 (1), P30CA072720 (1), U01CA076576 (1)